Meeting
2019 ASCO Annual Meeting
CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).
Authors
Edward B. Garon
David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles, CA
Edward B. Garon , Andrea Ardizzoni , Fabrice Barlesi , Byoung Chul Cho , Pedro De Marchi , Yasushi Goto , Shun Lu , Luis G. Paz-Ares , David R. Spigel , Michael Thomas , Bijoyesh Mookerjee , Pilar Cazorla Arratia , Jason Baum , Yi-Yang Yvonne Lau , Zewen Zhu , James Chih-Hsin Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03447769
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8570)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8570
Abstract #
TPS8570
Poster Bd #
325b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
First Author: Tina Cascone
Poster
2020 ASCO Virtual Scientific Program
CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
First Author: Edward B. Garon
Poster
2018 ASCO Annual Meeting
Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
First Author: Hiran C. Fernando
Poster
2016 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.
First Author: Li Zhang